ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Alector, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.95+0.11 (+5.98%)
Close on Oct 19, 2026
- Market cap
- $216.89M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.09 (−35.86%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Alector, Inc. saw revenue fall 82.9% to $13.86M over the twelve months to Jun 30, 2026. Free cash flow was -$158.39M.
Revenue
$13.86M
-82.9% vs. a year earlier
Operating income
-$126.49M
TTM Q2 2026
Free cash flow
-$158.39M
TTM Q2 2026
EPS, diluted
-$1.10
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $216.89M
- P/E ratio
- –
- Price to sales
- 15.65
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -73.03%
Fundamentals
- Revenue
- $13.86M
- Net income
- -$117.85M
- EPS, diluted
- -$1.10
- Free cash flow
- -$158.39M
- Book value per share
- -$0.09
- Diluted shares
- 111M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$13.86M-82.9% YoY
Operating income
-$126.49M
Net income
-$117.85M
EPS, diluted
-$1.10
Free cash flow
-$158.39M
Reported periodTrailing twelve months